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Abstract
IL-18, an immunoregulatory and proinflammatory cytokine, has
been shown to play an important pathogenic role in Th1-driven
autoimmune disorders. In this study, we evaluated the
circulating levels and salivary-gland expression of IL-18 in
patients with Sjögren's syndrome (SS), a mainly Th1-mediated
disease. IL-18 serum levels were measured by ELISA in 37
patients with primary SS, 42 with rheumatoid arthritis, and 21
normal controls. We demonstrated high IL-18 serum levels in
SS, similar to those in rheumatoid arthritis patients and
significantly higher than in controls (P < 0.01). In addition, IL-18
serum concentrations were significantly higher in anti-SSA/Ro+
and anti-SSB/La+ than in anti-SSA/Ro- and anti-SSB/La- SS
patients (respectively, P  = 0.01, P  < 0.01). Serum IL-18
correlated strongly with anti-SSA/Ro (P = 0.004) and anti-SSB/
La (P  = 0.01) titers. Salivary gland IL-18 expression was
investigated by single/double immunohistochemistry in 13
patients with primary SS and in 10 with chronic sialoadenitis,
used as controls. The expression of IL-18 was also examined in
periductal inflammatory foci in relation to the acquisition of
features of secondary lymphoid organs such as T–B
compartmentalization, formation of follicular dendritic cell
networks, and presence of germinal-center-like structures. IL-18
expression in SS salivary glands was detected in 28 of 32
periductal foci of mononuclear cells (87.5%), while no IL-18
production by infiltrating cells was detected in patients with
chronic sialoadenitis. Within the inflammatory foci, IL-18
immunoreactivity co-localized almost exclusively with CD68+
macrophages. In addition, IL-18 was found in 15 of 19 foci
(78.9%) with no evidence of T–B cell compartmentalization
(nonsegregated) but in 100% of the segregated aggregates,
both in T- and B-cell-rich areas. Strikingly, IL-18 was strongly
expressed by CD68+ tingible body macrophages in germinal-
centre-like structures both in SS salivary glands and in normal
lymph nodes. IL-18 expression was observed in the ducts of all
SS biopsies but in only 4 of 10 patients with nonspecific chronic
sialoadenitis (P < 0.01). This study provides the first evidence of
increased circulating levels and salivary gland expression of IL-
18 in SS, suggesting an important contribution of this cytokine
to the modulation of immune inflammatory pathways in this
condition.
Keywords: chronic sialoadenitis, germinal centre, interleukin-18, Sjögren's syndrome, tingible body macrophages
Introduction
Sjögren's syndrome (SS) is an autoimmune disease affect-
ing salivary and lacrimal glands, characterized by chronic
periductal mononuclear-cell infiltration and local autoanti-
body production, which lead to architectural destruction of
the glands, resulting in the classical clinical signs and
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symptoms of mouth and eye dryness. A large body of evi-
dence from human studies suggests that the local immune
response in SS is mainly Th1-mediated [1-6], although a
Th2-mediated process may contribute at different stages of
the disease [4,5]. The presence of Th1-related cytokines
has been demonstrated in salivary glands from patients
with SS both in terms of protein and mRNA expression.
Increased levels of IL-1β, IL-6, tumor necrosis factor (TNF)-
α, and IFN-γ have been reported in saliva from patients with
SS in comparison with controls with histologically normal
salivary glands, confirming the role of Th1-cell-mediated tis-
sue damage [2]. However, little is known in SS regarding
the molecules acting upstream of the immune-mediated
events that lead to the amplification of the inflammatory
cascade.
IL-18, although capable of inducing Th2 cytokines in an IL-
4 independent manner [7], has been conclusively shown to
be a critical regulator of Th1 responses [8]. IL-18 was ini-
tially identified as a major inducer of IFN-γ [9] and were
shown to be instrumental in Th1 cell induction and activa-
tion in the presence of IL-12 [10]. Accordingly, functional
IL-18R is expressed on mature Th1 but not Th2 lym-
phocytes [11]. Furthermore, IL-18 has more recently been
shown to be capable of directly inducing expression of
proinflammatory cytokines such as TNF-α and IL-1β in
mature Th1 cells, macrophages, and natural killer cells [12-
14], to up-regulate production of both CC and CXC chem-
okines [15], to enhance expression of costimulatory mole-
cules such as CD40L and CD86 [16,17], and to induce
tissue damage through the induction of cell-mediated cyto-
toxicity [18-21] and the release of matrix metalloprotein-
ases [22,23].
This wide range of proinflammatory properties renders this
cytokine a crucial candidate mediator of chronic inflamma-
tion, as demonstrated both in animal models of autoimmu-
nity and human autoimmune diseases [13,24-32]. To date,
however, the expression and function of IL-18 in the
autoimmune sialoadenitis of SS has not been investigated,
aside from a recently reported study [3] in which the mRNA
expression of several cytokines (including IL-18) in minor
salivary gland biopsies from patients with SS was evalu-
ated. Thus, so far there are no definite reports regarding the
expression of IL-18 at protein level in salivary glands of
patients with SS. This is of particular relevance, because IL-
18 is synthesized as 23-kDa pro-IL-18 and undergoes
post-translational modifications, mainly upon cleavage by
caspase 1, before it can function as a mature, active, 18-
kDa glycoprotein [33]. In addition, there are no data
addressing the relationship between IL-18 expression and
local or systemic manifestation of SS.
The aims of the present study were, first, to evaluate IL-18
serum concentration in patients with primary SS and its
relationship with autoantibody production and clinical
parameters of this condition. Second, since SS is mainly a
localized disorder, we examined the expression and distri-
bution of IL-18 in salivary glands of SS. Third, we charac-
terized the nature of IL-18-producing cells within the
salivary glands. Fourth, we assessed the relationship
between IL-18 expression and the histomorphological
characteristics of the periductal immune/inflammatory infil-
trates. The results provided in this study strongly support a
prominent role for IL-18 in the local immune processes in
salivary glands of patients with SS.
Materials and methods
Serology
Thirty-seven consecutive patients with primary SS were
enrolled in this study (35 females, 2 males; mean age
[range] 54.1 years [28–77], mean disease duration [range]
71.2 months [2–360]). Patients were classified as having
SS on the basis of the recently revised criteria of the Amer-
ican–European Consensus Group [34]. The presence of
other, underlying autoimmune diseases or hepatitis C virus
infection was carefully excluded. As negative control popu-
lation, sera from 21 normal healthy subjects matched for
sex and age were studied, while sera from 42 patients with
rheumatoid arthritis (RA) classified according to American
Rheumatism Association criteria were used as disease
controls. From each patient and control a blood sample
was taken and sera were stored at -20°C until they were
tested. Patients with SS were also analyzed for the pres-
ence of extraglandular manifestations such as arthralgia/
arthritis, cryoglobulinemia, Raynaud's phenomenon, and
hepatic, pulmonary, or renal involvement. Twelve patients
with SS had extraglandular manifestations (four arthralgia/
arthritis, three Raynaud's phenomenon, two pleuritis, two
cutaneous vasculitis, one renal involvement).
Antinuclear antibodies were evaluated by indirect immun-
ofluorescence using Hep2 cells as substrate. Sera were
diluted 1:40 before the immunofluorescence assay. Rheu-
matoid factor was detected using an immunonephelometry
test (Behring, Marburg, Germany) as described elsewhere
[35].
Anti-SSA/Ro and anti-SSB/La antibodies of IgG isotype
were measured by commercial enzyme-linked immunosorb-
ent assay (ELISA) (Diamedix, Miami, FL, USA). Results
were expressed in IU in accordance with the manufac-
turer's instructions, and values above 20 IU were consid-
ered positive.
Anti-α-fodrin antibodies of both IgA and IgG isotypes were
tested using a commercial ELISA (Aesku.lab Diagnostika,
Wendelsheim, Germany). Results were expressed in U/ml,
and values above 5 U/ml and 6 U/ml, respectively, were
considered positive.Available online http://arthritis-research.com/content/6/5/R447
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IL-18 serum levels were detected as previously reported
[36]. Briefly, an anti-IL-18 monoclonal antibody (R&D Sys-
tems, Minneapolis, MN, USA) was used to coat (2 µg/ml in
PBS) a polystyrene ELISA plate (Maxisorb), which was
then incubated overnight at room temperature (RT). Plates
were then blocked for 2 hours at RT with PBS/BSA (1%),
sucrose (5%). After a washing with PBS–Tween 20
(0.05%), a solution made of TBS–BSA(0.1%)–Tween 20
(0.05%) was used to dilute standards (rhIL-18, R&D Sys-
tems) and sera. After 2 hours of incubation and further
washing, a secondary biotinylated antibody (R&D Systems)
was added (250 ng/ml) and incubated for 2 hours at RT.
After further washing, peroxidase-conjugated streptavidin
was added and incubated for 20 min at RT. The reaction
was then developed with a solution of tetramethylbenzidine
in the presence of H2O2, stopped with 4 N sulfuric acid,
and read at 450 nm wavelength.
Immunohistochemistry (IHC)
Tissue samples
Formaldehyde-fixed, paraffin-embedded tissue samples
were obtained from minor labial salivary gland biopsies of a
smaller subset of 13 patients with histologically proven SS
(i.e. with focus score ≥ 1) (11 females, 2 male; mean age
[range] 52.1 years [36–67], mean disease duration [range]
70.8 months [24–180], 9 [69%] positive for anti-Ro and/or
anti-La, 9 [69%] for rheumatoid factor, and 10 [77%] for
antinuclear antibodies) and from 10 patients with nonspe-
cific chronic sialoadenitis as controls. All samples were
obtained, after informed consent, during routine diagnostic
procedures. Minor salivary gland biopsies from patients
with chronic sialoadenitis showed no infiltration or the pres-
ence of a diffuse mononuclear infiltration in the absence of
focal organization. In most SS patients and controls, it was
possible to analyze multiple biopsies taken at the same
time. Two samples of parotid gland from SS patients were
studied but not considered in the overall evaluation and sta-
tistical analysis. Histological evaluation of the salivary
glands was performed according to the classification of
Chisholm and Mason [37] and a periductal mononuclear-
cell aggregate was defined as a focus when at least 50
periductal mononuclear cells with focal organization were
counted. The histological evaluation of the number of foci,
the presence of IL-18 in inflammatory foci and ducts, the
degree of organization of the mononuclear aggregates, and
the presence of germinal centers (GCs) were assessed
blind by two observers (MB and FB). A periductal inflamma-
tory focus was considered positive for IL-18 when at least
three cells were stained within the focus.
Normal human lymph nodes were obtained from patients
requiring vascular surgery. Procedures were performed
after informed consent approved by the hospital Ethics
Committee (LREC no. 99/03/19).
Primary antibodies
Mouse monoclonal anti-human IL-18 (IgG1 clone 2D3B6)
was used to detect IL-18 [13]. Monoclonal antibodies
directed against CD68 (macrophages) (clone PG-M1;
DAKO A/S, Cambridge, UK), CD20 (B lymphocytes)
(clone L26; DAKO), CD21 (follicular dendritic cells
[FDCs]) (clone 1F8; DAKO), and rabbit polyclonal anti-
CD3 (T lymphocytes) (Cod A0452; DAKO) were also
used.
Detection of IL-18 expression, identification of IL-18-
producing cells, and characterization of the periductal 
mononuclear-cell infiltrates in salivary glands of patients 
with SS and controls
For IL-18 detection, formalin-fixed, paraffin-embedded 3-
µm sections were dewaxed in xylene, rehydrated through
graded alcohol solutions, and washed in TBS, and antigen
was retrieved after proteolytic digestion with a solution of
0.1% trypsin in phosphate-buffered saline (PBS), pH 7.3.
After three washings in Tris-buffered saline (TBS), sections
were incubated at RT for 60 min at RT with anti-IL-18 at the
appropriate dilution in TBS containing 0.1% bovine serum
albumin (BSA). Sections incubated with an isotype-
matched control antibody were used as negative control.
After exposure to the primary antibody, the sections were
washed three times in TBS and incubated for 30 min at RT
with a DAKO Envision alkaline-phosphatase-conjugated
polymer. After three washings with TBS, colour reaction
was developed using Vector Red (Vector Laboratories,
Peterborough UK) and slides were slightly counterstained
with Mayer's hematoxylin (Sigma, Poole, Dorset, UK), dehy-
drated through graded ethanol solutions and xylene, and
mounted in DePex (BDH, Poole, Dorset, UK).
In order to identify the cell type expressing IL-18 in the
inflammatory infiltrates, double IHC was performed for
CD68/IL-18 using the DAKO EnVision Doublestain Sys-
tem. Briefly, for double staining, after antigen unmasking
with 0.1% trypsin in PBS, endogenous peroxidase was
blocked for 5 min at RT, and primary anti-CD68 antibody
appropriately diluted in TBS/0.1% BSA was added. After
the sections had been incubated for 1 hour and washed, a
horseradish-peroxidase-labelled polymer was added and
sections were incubated for 30 min at RT. After further
washing, a colour reaction was developed using 3,3'-diami-
nobenzidine (Sigma) substrate-chromogen until optimal
staining was achieved, and the section was blocked with
Doublestain Block for 3 min at RT. The sections were
rinsed in TBS and stained for anti-IL-18 as described
above. To verify the specificity of the staining, sections with
omission of the first, the second, or both of the primary anti-
bodies were used as negative controls (see Fig. 5).
In order to examine the relationship of IL-18 expression and
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inflammatory foci, samples were analyzed for T and B lym-
phocytes, the presence of FDCs, and the appearance of
GC-like structures. Sections were double-stained for CD3
(T cells) and CD20 (B cells) using the DAKO EnVision
Doublestain System and single-stained for FDC (CD21).
For CD3/CD20 double staining, we adopted the same pro-
tocol described above for CD68–IL-18, with the exception
of a different procedure for antigen unmasking, in that sec-
tions were heated for 45 min at 95°C in 0.02 Hcitrate buffer
(pH 6) before primary antibodies were added. For CD21,
we used a standardized protocol using proteolytic diges-
tion as antigen-retrieving method and overnight incubation
with the primary antibody at appropriate dilution. On the
basis of the CD3, CD20, and CD21 staining, lymphocytic
foci were classified either as nonsegregated (when no
clear compartmentalization of T and B cells in discrete
areas could be recognized) or as segregated (when inflam-
matory aggregates displayed a well defined organization in
separated T- and B-cell-rich areas), with or without ectopic
GC-like structures identified on the basis of the histologic
appearance and confirmed by the presence of FDC net-
works, as previously described by Stott and co-workers
[38].
Statistical analysis
A two-tailed Mann–Whitney U test was used to compare
continuous variables in the different groups. Spearman's
rank correlation was performed to correlate IL-18 serum
concentration with the titer of serum antibodies and with
clinical parameters. A χ2 test with Yates' correction when
required or Fisher's exact test when appropriate was used
to evaluate associations of qualitative variables in the differ-
ent groups. P  < 0.05 was considered statistically
significant.
Results
IL-18 concentration in the serum of patients with SS in 
comparison with normal and diseased controls, and its 
relationship with autoantibody production
IL-18 is increased in the systemic circulation of autoim-
mune diseases such as RA and Crohn's disease, in which
the principal site of production of this cytokine has been
demonstrated to reside in the inflamed target tissue
[13,29,39,40]. IL-18 serum concentrations (mean ± SEM)
were significantly higher (379 ± 45 pg/ml) in patients with
SS than in normal controls (196 ± 27 pg/ml; P < 0.01) and
were comparable to those found in patients with RA (477
± 86 pg/ml; PNS). As expected, IL-18 serum levels in RA
patients were also significantly higher than in the control
population (P < 0.05).
To examine the relationship between IL-18 serum levels
and autoantibody production, we categorized patients on
the basis of anti-SSA/Ro, anti-SSB/La, anti-α-fodrin anti-
bodies, antinuclear antibodies, and rheumatoid factor. Anti-
SSA/Ro and anti-SSB/La antibodies were found in 25
(68%) and 17 (46%) of 37 SS patients, respectively. Anti-
α-fodrin antibodies of IgA isotype were found in 22 of 37
patients (59%), while 6 patients (16%) expressed anti-α-
fodrin IgG. In addition, antinuclear antibodies were
detected in 29 SS patients (78%), while rheumatoid factor
was present in 27 (73%).
When patients with SS were grouped on the basis of the
presence or absence of the various autoantibodies, serum
IL-18 was found to be significantly increased in SS patients
who were anti-SSA/Ro+ (443 ± 57 pg/ml) and anti-SSB/
La+ (497 ± 78 pg/ml) in comparison with anti-SSA/Ro-
(245 ± 58 pg/ml; P = 0.01) and anti-SSB/La- (278 ± 41
pg/ml, P < 0.01) patients (Fig. 1b,1c, respectively). Impor-
tantly, there was direct correlation between IL-18 serum
levels and autoantibody production. Serum IL-18 concen-
tration positively correlated with both anti-SSA/Ro (r  =
0.466, P = 0.004) and anti-SSB/La serum titers (r = 0.414,
P  = 0.01). In contrast, no significant difference was
observed in IL-18 serum levels comparing patients with SS
with or without anti-α-fodrin IgG or IgA antibodies, antinu-
clear antibodies, and rheumatoid factor.
Finally, we analyzed IL-18 serum concentrations and
autoantibody production in relationship with the presence
or absence of extraglandular involvement. No significant
difference was found in IL-18 serum concentrations or
autoantibody levels among these groups.
Tissue distribution of IL-18 expression and identification 
of IL-18-producing cells in salivary glands of patients 
with SS and chronic sialoadenitis
IL-18 expression in inflammatory foci
On the basis of the histological evaluation of the salivary
glands performed according to the Chisholm and Mason
classification [37], we could identify in patients with SS a
total of 32 periductal inflammatory aggregates fulfilling
focus definition, while no foci were observed in chronic
sialoadenitis.
IL-18 expression was detected in periductal mononuclear
cells in all 13 SS samples studied, with a total of 28 of 32
inflammatory foci (87.5%). A considerable amount of IL-18-
producing cells (mean ± SEM number of positive cells/
focus = 9.6 ± 1.4) was found to be distributed scattered
within the focal infiltrates. Typical distribution of IL-18
within a periductal focus is shown in Fig. 2a,2b. Moreover,
cells expressing IL-18 were frequently observed surround-
ing acinar structures, but only in close proximity to the
inflammatory aggregates (Fig. 2c), with no IL-18 expression
in areas devoid of infiltrating cells. No IL-18 production by
infiltrating cells within the salivary glands was detected in
any patient with chronic sialoadenitis (Fig. 2d,2e,2f).Available online http://arthritis-research.com/content/6/5/R447
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Identification of IL-18-producing cells in inflammatory foci
Morphological analysis demonstrated that infiltrating mono-
nuclear cells expressing IL-18 had abundant cytoplasm and
vesicular nuclei, compatible with a monocyte-derived cell
lineage (Fig. 2a,2b,2c). Monocyte/macrophage cells have
been shown to represent the major source of IL-18 in other
chronic inflammatory conditions such as RA and Crohn's
disease [13,29]. Using double IHC for IL-18 and CD68, we
observed IL-18 exclusively in CD68+ cells adjacent to and
within the foci (Fig. 2g,2h). IL-18+/CD68+ macrophages
were detected only in the context of lymphocytic infiltration
in the periductal foci, while CD68+ macrophages outside
the focal infiltrates exhibited no detectable IL-18 (Fig. 2i).
Thus, although macrophages are known to produce IL-18
constitutively, the discrete pattern of expression of IL-18
only in macrophages within the periductal infiltrate is sug-
gestive of an inducible phenomenon associated with the
microarchitectural organization of periductal aggregates.
Figure 1
Serum IL-18 concentrations in patients with Sjögren's syndrome (SS) and relationship with the presence of anti-SSA/Ro and anti-SSB/La  antibodies Serum IL-18 concentrations in patients with Sjögren's syndrome (SS) and relationship with the presence of anti-SSA/Ro and anti-SSB/La antibod-
ies. Box–whisker plots showing serum IL-18 concentration in patients with SS compared with patients with rheumatoid arthritis (RA) and normal 
healthy subjects (NHS) (a), and in patients with SS who are positive or negative for anti-SSA/Ro (b) or anti-SSB/La antibodies (c). See text for sta-
tistical analysis.
Figure 2
Immunohistochemical (IHC) detection of IL-18 in salivary glands of patients with Sjögren's syndrome (SS) (a–c,g–i) and in nonspecific chronic  sialoadenitis (d–f) Immunohistochemical (IHC) detection of IL-18 in salivary glands of patients with Sjögren's syndrome (SS) (a–c,g–i) and in nonspecific chronic 
sialoadenitis (d–f). (a,b) Paraffin-embedded section of glands in SS, showing high amounts of IL-18-expressing cells distributed in a scattered fash-
ion within the periductal mononuclear infiltrate. (c) IL-18-positive cells were also observed surrounding acini (arrows) in proximity with the inflamma-
tory aggregate. (d–f) Paraffin-embedded sections of glands from patients with nonspecific chronic sialoadenitis, demonstrating the absence of IL-18 
expression in mononuclear cells in nonfocal periductal infiltrates. (g) Paraffin-embedded sections of glands from patients with SS, double-stained for 
CD68 (brown) and IL-18 (purple), showed exclusive co-localization of IL-18 expression in most of the CD68+ macrophages (arrows) within the peri-
ductal inflammatory infiltrates. (h) Macrophages expressing a large amount of IL-18 (arrows) were also observed surrounding acini in contiguity with 
a focal lymphocytic aggregate. (i, same sample as g) Conversely, CD68+ macrophages adjacent to a nonfocal infiltrate remained single-stained. 
Original magnification (a,b,d) × 100, (c,e–i) × 200.Arthritis Research & Therapy    Vol 6 No 5    Bombardieri et al.
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Detection of IL-18 in ductal epithelial cells
IL-18 immune staining was detected in epithelial cells of
ducts in all SS samples, while in patients with nonspecific
chronic sialoadenitis, ductal IL-18 staining was observed
only in 4 of 10 patients (P < 0.01). Notably, IL-18 expres-
sion in SS ducts showed considerable variability (mean
percentage of positive ducts 46.3, range 18–82). Moreo-
ver, variable levels of IL-18 expression were detected in dif-
ferent ducts within the same gland (Fig. 3a), as well as
among different samples studied. In addition, ductal IL-18
expression was observed both in the presence and in the
absence of IL-18-producing cells in the periductal inflam-
matory focal infiltrate (Figs 2b,3b, respectively). Finally,
ductal IL-18 expression was also found in the absence of a
focal infiltrate (Fig. 3c) as well as in ducts surrounded by
extensive fibrosis (Fig. 3d). Of relevance, in contrast to duc-
tal epithelial cells, no staining for IL-18 was found in acinar
cells (Fig. 3a,3d). In a minority of patients with chronic
sialoadenitis, we observed similar ductal staining patterns
(Fig. 3e,3f), with the exception of a consistently negative
periductal infiltration for IL-18.
Relationship between IL-18 expression and lymphoid 
organization of inflammatory foci in salivary glands of 
patients with SS in comparison with secondary lymphoid 
organs
Expression of IL-18 by CD68+ macrophages only within
periductal inflammatory foci rather than diffuse cellular infil-
trate suggested that a 'critical mass' might be required for
IL-18 expression. Moreover, anti-SSA/Ro and SSB/La
autoantibodies are known to be principally produced in the
salivary glands with lymphoid-like features [41]. For these
reasons, IL-18 expression was analyzed in relationship with
the level of lymphoid organization of the foci in terms of T–
B cell segregation and the appearance of GC-like struc-
tures identified as described in Materials and methods, and
foci were classified as nonsegregated and segregated with
or without GC-like structures.
Of the 32 periductal inflammatory foci identified in the sam-
ples studied, 19 (59.4%) showed predominance of CD3+
lymphocytes mixed with CD20+ cells without clear com-
partmentalization of the two cell subsets (Fig. 4a). The
remaining 13 inflammatory foci (40.6%) showed an
increased number of B cells with a variable degree of B-T-
cell compartmentalization into discrete areas (Fig. 4b). Fur-
thermore, on the basis of the morphological analysis, con-
firmed by the presence of FDC network, GCs were
detected in 6 of 32 (18.7%) periductal foci (Fig. 4c,4d). In
the nonsegregated foci, IL-18 was expressed in 15 of 19
(78.9%), while IL-18-producing cells were detected in
100% of the segregated aggregates, both in T- and B-cell-
rich areas (Fig. 5a,5b). IL-18 was also found to be highly
expressed in all ectopic GC-like structures (Fig. 5c) in SS
salivary glands. Double IHC confirmed that IL-18 was pro-
duced by CD68+ tingible body macrophages within the
GCs (Fig. 5d). In order to assess whether the production of
IL-18 in lymphoid-like structures in SS salivary glands is
peculiar to this condition or is a common feature of second-
ary lymphoid-organ follicles, we performed a comparative
IHC analysis in normal lymph nodes. This analysis demon-
strated a very similar pattern, with high IL-18 expression in
large mononuclear cells within GC with engulfed apoptotic
bodies (Fig. 5e). Consistent with this, IL-18 immune reac-
tivity appeared to overlap with CD68+ tingible body macro-
phages (Fig. 5g). Co-localization of IL-18 and CD68
staining was clearly confirmed by double IHC (Fig. 5f).
Discussion
In this study, we report the first demonstration of increased
systemic and local expression of IL-18 in patients with SS.
SS is an autoimmune disease characterized by the destruc-
tion of epithelial cells in salivary and lacrimal glands, leading
Figure 3
IL-18 expression in salivary gland ducts of patients with Sjögren's syn- drome (SS) (a–d) and nonspecific chronic sialoadenitis (e,f) IL-18 expression in salivary gland ducts of patients with Sjögren's syn-
drome (SS) (a–d) and nonspecific chronic sialoadenitis (e,f). IL-18-
positive ducts were detected in all the SS samples but in only a minority 
of those from chronic sialoadenitis. A considerable range of variability of 
IL-18 expression was observed in ducts among different samples. 
Within the same glandular lobule, positive and negative (arrowheads) 
adjacent ducts were observed (a). Ductal IL-18 expression was found 
in ducts surrounded (b) and not surrounded (c) by focal infiltrate, as 
well as in ducts characterized by periductal fibrosis (d). In contrast to 
ductal epithelial cells, no staining for IL-18 was found in acinar cells 
(a,d, stars). In a minority of patients with chronic sialoadenitis, we 
observed similar ductal staining patterns. Representative examples of 
positive (e) and negative (f) ductal IL-18 staining in different patients 
with chronic sialoadenitis are shown. Original magnification × 200.Available online http://arthritis-research.com/content/6/5/R447
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to exocrine dysfunction. The histological hallmark of the
disease is the presence of a periductal mononuclear-cell
infiltrate that can become organized in follicle-like struc-
tures. Chronic inflammation within the salivary glands leads
to the local production of autoantibodies and cell-mediated
mechanisms of tissue damage. Although the presence of
Th2 cytokines in salivary glands of patients with SS has
been demonstrated [4,5], several lines of evidence suggest
that the immune cellular infiltrate in SS is mainly repre-
sented by CD4 lymphocytes expressing a Th1 profile.
Accordingly, enhanced production of Th1-related
cytokines such as IFN-γ, TNF-α, IL-2, and IL-1β has been
demonstrated, both by mRNA and protein expression anal-
ysis [1-5,42,43]. In particular, it has been observed that
CD4+ T cells infiltrating salivary glands from patients with
SS produce over 40-fold more IL-2 and IFN-γ mRNA than
peripheral blood CD4 T cells isolated from the same
patients as well as from salivary glands of normal controls
[42]. In addition, IFN-γ mRNA expression from cultured lym-
phocytes isolated from salivary glands of patients with SS
correlates with the degree of lymphocytic infiltration in sali-
vary gland, a finding that indirectly suggests that the
increase in lymphocytic infiltration is accompanied by the
up-regulation of Th1 cytokines [4]. Despite these observa-
tions, factors regulating this Th1 response in SS have not
been well characterized.
The crucial role for IL-18 in the development of Th1 immune
responses has been established since its identification as
a major IFN-γ-inducing factor [9] in cooperation with IL-12
[44]. Furthermore, IL-18 has been demonstrated to exert
additional proinflammatory properties such as the ability to
directly stimulate the production of TNF-α in macrophages,
CD3+/CD4+ cells, and natural killer cells, with subsequent
release of IL-1β and IL-8 [13,15]; to up-regulate the expres-
sion of both CC and CXC chemokines [12]; and to stimu-
late adhesion molecule expression in different cell types
[45]. The broad range of proinflammatory activities and the
demonstrated pathogenic role of IL-18 in other chronic
Th1-mediated autoimmune diseases such as RA and
Crohn's disease [13,28,29,39] make this cytokine a prime
candidate also in the pathogenesis of SS.
Increased serum levels and salivary gland expression of IL-
18 in patients with SS is in keeping with an active role for
this cytokine in the tissue pathogenesis. IL-18 serum con-
centrations in patients with primary SS were significantly
higher than in normal controls and comparable with those
observed in patients with RA, a disease in which elevated
IL-18 serum levels have been reported by our group and
others [28,36]. Serum IL-18 levels were significantly
increased in SS patients with anti-SSA/Ro+ and anti-SSB/
La+ antibodies. The strength of this association was further
emphasized by the positive correlation of IL-18 serum lev-
els with both anti-SSA/Ro and anti-SSB/La serum titers.
The observation that anti-SSA/Ro and anti-SSB/La serum
levels have been shown to correlate with the presence of
anti-SSA/Ro- and anti-SSB/La-producing cells in the sali-
vary glands [46] induced us to investigate IL-18 expression
at this site.
IL-18 protein was strongly expressed in periductal mononu-
clear cells infiltrating the salivary glands of all SS patients
but not in patients with chronic sialoadenitis. Phenotypic
analysis demonstrated that in SS samples, IL-18
production within the periductal inflammatory infiltrate was
exclusively confined to CD68+ macrophages. Interestingly,
the expression of IL-18 by CD68+  macrophages was
observed only within periductal inflammatory foci and in
periacinar macrophages adjacent to focal infiltrates, and
not in isolated macrophages, an observation that suggests
an activation state of macrophages. These observations
reinforce an otherwise underestimated role of this cell type
in the pathogenesis of SS, as also recently suggested [47].
In addition to macrophages, ductal epithelial cells
appeared to represent a major source of IL-18 in SS sali-
vary glands. Although the range of ductal IL-18 expression
was wide (18–82% positive ducts), expression at some
level was detected in all SS patients studied, but interest-
ingly only in a minority of patients with chronic sialoadenitis.
No staining for IL-18 was found in acinar cells, indicating
that IL-18 production is confined exclusively to ductal epi-
thelial cells. The detection of IL-18 in this cell type is in
Figure 4
Degree of lymphoid organization of the periductal lymphocytic infiltrates  in salivary gland of patients with Sjögren's syndrome (SS) Degree of lymphoid organization of the periductal lymphocytic infiltrates 
in salivary gland of patients with Sjögren's syndrome (SS). Paraffin-
embedded sections were double-stained for CD3 (brown) and CD20 
(purple) (a–c) and single-stained with CD21 (d). Inflammatory foci were 
classified as nonsegregated when T and B lymphocytes were not com-
partmentalized in distinct areas (a), as segregated in the presence of 
evident compartmentalization of T and B cells (b), and as segregated 
with germinal-centre-like structures (arrow) when a clear histological 
appearance (c) and networks of CD21+ follicular dendritic cells (d) 
were observed. Original magnification × 200.Arthritis Research & Therapy    Vol 6 No 5    Bombardieri et al.
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accordance with the notion that, although classical antigen-
presenting cells such as monocytes/macrophages and
dendritic cells are regarded as the pivotal source of IL-18
in the regulation of Th1-mediated immune responses [7],
nonimmune cell types can also produce IL-18 [13,29,48].
Notably, in salivary gland of SS, ductal IL-18 expression
was observed both in the presence and in the absence of
IL-18-producing cells in the periductal inflammatory foci
and was also found in the absence of a focal infiltrate as
well as in ducts surrounded by extensive fibrosis. The lack
of association between ductal IL-18 expression and the
presence of periductal inflammation in all cases raises the
intriguing possibility that the dysregulation of ductal IL-18
expression may become uncoupled from or independent of
the level of cellular infiltration. In addition, the demonstra-
tion of increased ductal expression of IL-18 in SS would be
in keeping with other autoimmune conditions such as
Crohn's disease and psoriasis, in which a dysregulation of
IL-18 expression in intestinal epithelial cells and skin kerat-
inocytes, respectively, is considered an important compo-
nent in the development of local chronic inflammation
[29,48]. However, whether up-regulation of IL-18 expres-
sion in epithelial cells in SS, as well as in other autoimmune
conditions, is an initiating event or is acquired later in the
course of the inflammatory process is still unknown.
Because of the strong evidence that IL-18 expression was
present only within the inflammatory infiltrates showing
focal organization, we analyzed the anatomical relationship
between the presence of IL-18 within the focus, the main
lymphocytic subsets, and the degree of structural organiza-
tion of the periductal inflammatory aggregates. While we
found expression of IL-18 by infiltrating cells in the majority
but not all of the nonsegregated foci, a large number of IL-
18-producing cells was detected in 100% of the aggre-
gates with well demarcated T–B-cell compartmentalization
both in T- and B-cell areas. Thus, the increasing expression
of IL-18 in larger and more structured infiltrates would sug-
gest that IL-18 is involved in the amplification of the chronic
inflammatory processes leading to the acquisition of a more
complex organization of the periductal foci. This possibility
is further supported by the observation of prominent IL-18
expression in all the ectopic GC-like structures in salivary
glands of patients with SS. IL-18 production within these
structures was exclusively co-localized with CD68+ tingible
body macrophages. An identical pattern of IL-18 expres-
sion was also observed in secondary lymphoid organs of
normal individuals. In this regard, a recent study demon-
strated that IL-18R is expressed and functional on GC B
cells isolated from human tonsil and is up-regulated by IL-
12 [49]. To our knowledge, this is the first report of IL-18
production within the GC by tingible body macrophages
and suggests an active involvement of tingible body macro-
phages producing high levels of IL-18 in the regulation of
GC reaction.
Figure 5
Relationship between IL-18 expression and B-/T-cell compartmentaliza- tion (a,b) and germinal-center-like (GC-like) structures (c,d) in the sali- vary glands of patient with Sjögren's syndrome (SS) and, for  comparison, in normal lymph nodes (e–h) Relationship between IL-18 expression and B-/T-cell compartmentaliza-
tion (a,b) and germinal-center-like (GC-like) structures (c,d) in the sali-
vary glands of patient with Sjögren's syndrome (SS) and, for 
comparison, in normal lymph nodes (e–h). Representative section of a 
large segregated aggregate double-stained for CD20 (brown) and IL-
18 (purple) (a), and (b) sequential section with an irrelevant antibody 
replacing the anti-CD20, demonstrating the presence of IL-18-produc-
ing cells both in the T-cell (a, arrows) and B-cell (b, arrows) areas. (c) 
Single staining for IL-18, demonstrating a large number of IL-18-pro-
ducing cells within ectopic GC-like structures in salivary gland from SS. 
(d) Double immunohistochemical staining for CD68 (brown) and IL-18 
(purple), demonstrating the exclusive co-localization of IL-18 with 
CD68 macrophages. (e–h) An identical pattern of distribution in terms 
of IL-18 expression and co-localization with CD68 macrophages was 
observed in GCs of secondary lymphoid organs. Histomorphological 
analysis of the IL-18 positive cells within the GC showed evidence of 
engulfed apoptotic bodies in the cytoplasm (e) that identifies these 
cells as tingible body macrophages (TBMs). (f) Double immunohisto-
chemical staining for CD68/IL-18 confirmed the exclusive co-localiza-
tion of IL-18 with TBMs within the GC. Sequential sections in which the 
anti-CD68 (e), anti-IL-18 (g), or both the primary antibodies (h) were 
replaced with an isotype-matched irrelevant antibody confirmed the 
specificity of the double staining (h, negative control). Original magnifi-
cation (a–d) × 200, (e-h) × 400Available online http://arthritis-research.com/content/6/5/R447
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The relevance of IL-18 expression in B-cell-rich areas and
GC-like structures in salivary glands of patients with SS
relates to the demonstration that, as mentioned above,
serum levels of IL-18 in our SS population were increased
in patients positive for anti-SSA/Ro and anti-SSB/La in
comparison with patients who were negative for these anti-
bodies, and were closely correlated with the titers of these
autoantibodies. Although our study did not address the
direct relationship between IL-18 expression in GC-like
structures, their functionality, and local production of
autoantibodies, it has been reported that anti-SSA/Ro and
anti-SSB/La are produced in SS salivary glands [46], and
their serum levels correlate with the presence of ectopic
GC-like structures [41]. Finally, although a conclusive dem-
onstration of the functionality of ectopic GC-like structures
in SS is required, Ig V gene rearrangement analysis has
provided evidence of an antigen-driven B-cell response
within microdissected GC-like structures in salivary glands
of SS patients, suggesting their functionality in generating
a local (auto) antibody response [38]. In this regard, further
studies will be required to assess the functional role of IL-
18 in participating in physiologic and ectopic GC formation
and function.
Conclusion
In this study, we provide for the first time evidence of
increased serum levels of IL-18 in patients with SS, which
correlate with the production of autoantibodies. We also
demonstrated that IL-18 is expressed at high levels within
the inflammatory foci in salivary glands of patients with SS
but not in chronic sialoadenitis and is exclusively produced
by CD68+ macrophages within the periductal aggregates.
In addition, IL-18 expression in SS salivary glands was par-
ticularly associated with inflammatory foci that acquired
features of secondary lymphoid organs, with large amounts
of IL-18 expressed within ectopic GC-like structures by tin-
gible body macrophages. Similar findings were reproduced
in normal lymph node GCs. Finally, we demonstrated that
IL-18 was expressed in the salivary gland ducts of all SS
patients but in only a minority of patients with nonspecific
chronic sialoadenitis. Although further studies are needed
to ascertain the direct functional relevance of IL-18 in reg-
ulating immune responses in SS, our data suggest an
important contribution of this cytokine to the modulation of
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